Homology Medicines Inc (NASDAQ:FIXX) Receives $30.43 Average PT from Analysts

Share on StockTwits

Homology Medicines Inc (NASDAQ:FIXX) has earned a consensus rating of “Buy” from the ten research firms that are currently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and seven have issued a buy recommendation on the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $30.43.

FIXX has been the topic of a number of recent research reports. Chardan Capital restated a “buy” rating and set a $34.00 price target on shares of Homology Medicines in a research report on Monday, August 10th. Bank of America started coverage on shares of Homology Medicines in a research note on Thursday, June 25th. They set a “buy” rating and a $30.00 target price on the stock. HC Wainwright reduced their target price on shares of Homology Medicines from $37.00 to $30.00 and set a “buy” rating on the stock in a research note on Tuesday, August 11th. FIX started coverage on shares of Homology Medicines in a research note on Thursday, June 25th. They set a “buy” rating and a $30.00 target price on the stock. Finally, Zacks Investment Research raised shares of Homology Medicines from a “sell” rating to a “hold” rating in a research note on Monday, August 3rd.

FIXX traded down $0.16 on Tuesday, reaching $9.94. 590,113 shares of the company’s stock were exchanged, compared to its average volume of 475,650. The stock has a market cap of $449.47 million, a PE ratio of -3.58 and a beta of -0.25. Homology Medicines has a twelve month low of $9.19 and a twelve month high of $24.00. The stock’s fifty day moving average price is $12.64 and its 200-day moving average price is $14.78.

Homology Medicines (NASDAQ:FIXX) last posted its quarterly earnings results on Monday, August 10th. The company reported ($0.78) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.04). Homology Medicines had a negative return on equity of 53.10% and a negative net margin of 5,764.94%. Analysts expect that Homology Medicines will post -3.16 EPS for the current year.

A number of large investors have recently modified their holdings of the stock. Point72 Hong Kong Ltd purchased a new position in shares of Homology Medicines in the 2nd quarter valued at about $34,000. Bank of Montreal Can purchased a new position in shares of Homology Medicines in the 2nd quarter valued at about $42,000. Ameritas Investment Partners Inc. increased its holdings in shares of Homology Medicines by 43.8% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,003 shares of the company’s stock valued at $46,000 after purchasing an additional 915 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in shares of Homology Medicines in the 1st quarter valued at about $59,000. Finally, Marshall Wace LLP purchased a new position in shares of Homology Medicines in the 1st quarter valued at about $74,000. Hedge funds and other institutional investors own 83.28% of the company’s stock.

About Homology Medicines

Homology Medicines, Inc, a genetic medicines company, focuses on translating proprietary gene editing and gene therapy technologies into novel treatments for patients with rare diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing modality across a range of genetic disorders.

Further Reading: How to Track your Portfolio in Google Finance

Analyst Recommendations for Homology Medicines (NASDAQ:FIXX)

Receive News & Ratings for Homology Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Homology Medicines and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply